according to the American Cancer Society. GSK’s acquisition of IDRx will include IDRX-42 which is currently being developed and trialled as therapy for the treatment of gastrointestinal stomal ...

Pancreatic cancer remains a formidable foe, with the American Cancer Society estimating over 66,000 ... ONCY) (TSX: ONC), GSK plc (NYSE: GSK), AstraZeneca PLC (NASDAQ: AZN), Gilead Sciences ...

GSK isn't revealing the size of the OS improvement yet – it has promised to do so at the American Society for Haematology ... At this year's ASCO cancer congress in February, earlier results ...

The results were featured at the American Society of Haematology (ASH) annual meeting and, according to GSK, "support the potential ... treatment for the blood cancer. After being all but written ...

By sharing the stories of EDI champions in science, we hope to shed light on both the importance of diversity and the ...

The majority (41 of 53) of patients had their autoimmune or inflammatory disease diagnosed before cancer. The study was approved by ... T-cell therapy using paired McNemar's tests. ASTCT=American ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore the potential of cancer prevention through vaccination. The partnership ...

In 2000, the Union for International Cancer Control (UICC) named Feb. | In 2000, the Union for International Cancer Control named Feb. 4 World Cancer Day, with a goal of raising awareness of cancer ...

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines. The University of Oxford and GSK are to work on a vaccine to target cells in the ...

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target ...